Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil

Richard K. Bogan; Daniel O. Lee; Mark J. Buchfuhrer; Mark J. Jaros; Richard Kim; Gwendoline Shang

doi:10.3109/07853890.2015.1025825

Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil

Richard K. Bogan, Daniel O. Lee, Mark J. Buchfuhrer, Mark J. Jaros, Richard Kim, Gwendoline Shang

Neurology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Introduction. This pooled analysis investigated the effects of gabapentin enacarbil (GEn) on clinical correlates of sleep disturbance in adults with moderate-to-severe primary restless legs syndrome (RLS) and no-to-moderate or severe-to-very severe baseline sleep disturbance. Methods. Co-primary end-points were mean change from baseline to week 12 in International Restless Legs Scale (IRLS) total score and proportion of responders ('much'/'very much' improved) on the investigator-rated Clinical Global Impression-Improvement (CGI-I) scale (week 12). Pain, mood, individual IRLS items, and safety were assessed. Results. The modified intent-to-treat population was 671 adults randomized to GEn 600 mg (n = 161), GEn 1200 mg (n = 266), or placebo (n = 244). GEn significantly improved least squares mean change in IRLS total score from baseline versus placebo for no-to-moderate (GEn 600 mg,- 12.3; 1200 mg, - 11.3; placebo, - 7.7) and severe-to-very severe (- 16.6; - 17.0; - 12.7) groups (all P < 0.01). Significantly more GEn-treated patients (both doses) were CGI-I responders (week 12) versus placebo in both sleep subgroups (all P < 0.01). GEn substantially improved mood and pain scores for both sleep subgroups versus placebo. The most frequent treatment-emergent adverse events were somnolence and dizziness. Conclusion. GEn (600 mg and 1200 mg) was effective and well tolerated in adults with moderate-to-severe primary RLS regardless of baseline sleep disturbance level.

Original language	English
Pages (from-to)	269-277
Number of pages	9
Journal	Annals of Medicine
Volume	47
Issue number	3
DOIs	https://doi.org/10.3109/07853890.2015.1025825
State	Published - May 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Informa UK, Ltd.

Funding

sures: shareholder, Chief Medical Officer, and employee of SleepMed Inc.; Board of Directors of SleepMed Inc., First Community Corporation, SC and National Sleep Foundation; consultant to Aerial, Jazz, ApniCure, UCB, Teva; Speakers Bureau for Teva, Jazz, UCB, and XenoPort, Inc.; industry-funded research for GSK, Jazz, Vanda, Merck, Novo Nordisk, Pfizer, XenoPort, Eisai, Philips, ResMed, Apnicure, Sensory Medical, J & J, Apnex, and Fisher Paykel. D.O.L. is a consultant to GSK, Lundbeck, and XenoPort, Inc. M.J.B. is consultant and speaker for XenoPort, Inc. and UCB Pharma, and conducts research for Xenon. M.J.J. is a paid consultant of XenoPort, Inc. R.K. and G.S. are employees of and own stock in XenoPort, Inc. These studies and this analysis were conducted by XenoPort, Inc., Santa Clara, CA, USA. Medical writing support was provided by Sachi Yim from CodonMedical, an Ashfield Company, and was funded by XenoPort, Inc.

Funders	Funder number
XenoPort, Inc.

Keywords

Gabapentin enacarbil
Mood
Pain
Restless legs syndrome

ASJC Scopus subject areas

General Medicine

Access to Document

10.3109/07853890.2015.1025825

Fingerprint

Dive into the research topics of 'Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil'. Together they form a unique fingerprint.

Cite this

Bogan, R. K., Lee, D. O., Buchfuhrer, M. J., Jaros, M. J., Kim, R., & Shang, G. (2015). Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil. Annals of Medicine, 47(3), 269-277. https://doi.org/10.3109/07853890.2015.1025825

@article{79ef2c25975b40f38ed4b543bb8b66e7,

title = "Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil",

abstract = "Introduction. This pooled analysis investigated the effects of gabapentin enacarbil (GEn) on clinical correlates of sleep disturbance in adults with moderate-to-severe primary restless legs syndrome (RLS) and no-to-moderate or severe-to-very severe baseline sleep disturbance. Methods. Co-primary end-points were mean change from baseline to week 12 in International Restless Legs Scale (IRLS) total score and proportion of responders ('much'/'very much' improved) on the investigator-rated Clinical Global Impression-Improvement (CGI-I) scale (week 12). Pain, mood, individual IRLS items, and safety were assessed. Results. The modified intent-to-treat population was 671 adults randomized to GEn 600 mg (n = 161), GEn 1200 mg (n = 266), or placebo (n = 244). GEn significantly improved least squares mean change in IRLS total score from baseline versus placebo for no-to-moderate (GEn 600 mg,- 12.3; 1200 mg, - 11.3; placebo, - 7.7) and severe-to-very severe (- 16.6; - 17.0; - 12.7) groups (all P < 0.01). Significantly more GEn-treated patients (both doses) were CGI-I responders (week 12) versus placebo in both sleep subgroups (all P < 0.01). GEn substantially improved mood and pain scores for both sleep subgroups versus placebo. The most frequent treatment-emergent adverse events were somnolence and dizziness. Conclusion. GEn (600 mg and 1200 mg) was effective and well tolerated in adults with moderate-to-severe primary RLS regardless of baseline sleep disturbance level.",

keywords = "Gabapentin enacarbil, Mood, Pain, Restless legs syndrome",

author = "Bogan, {Richard K.} and Lee, {Daniel O.} and Buchfuhrer, {Mark J.} and Jaros, {Mark J.} and Richard Kim and Gwendoline Shang",

note = "Publisher Copyright: {\textcopyright} 2015 Informa UK, Ltd.",

year = "2015",

month = may,

day = "1",

doi = "10.3109/07853890.2015.1025825",

language = "English",

volume = "47",

pages = "269--277",

number = "3",

}

Bogan, RK, Lee, DO, Buchfuhrer, MJ, Jaros, MJ, Kim, R & Shang, G 2015, 'Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil', Annals of Medicine, vol. 47, no. 3, pp. 269-277. https://doi.org/10.3109/07853890.2015.1025825

Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil. / Bogan, Richard K.; Lee, Daniel O.; Buchfuhrer, Mark J. et al.
In: Annals of Medicine, Vol. 47, No. 3, 01.05.2015, p. 269-277.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome

T2 - Pooled analyses from 3 trials of gabapentin enacarbil

AU - Bogan, Richard K.

AU - Lee, Daniel O.

AU - Buchfuhrer, Mark J.

AU - Jaros, Mark J.

AU - Kim, Richard

AU - Shang, Gwendoline

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction. This pooled analysis investigated the effects of gabapentin enacarbil (GEn) on clinical correlates of sleep disturbance in adults with moderate-to-severe primary restless legs syndrome (RLS) and no-to-moderate or severe-to-very severe baseline sleep disturbance. Methods. Co-primary end-points were mean change from baseline to week 12 in International Restless Legs Scale (IRLS) total score and proportion of responders ('much'/'very much' improved) on the investigator-rated Clinical Global Impression-Improvement (CGI-I) scale (week 12). Pain, mood, individual IRLS items, and safety were assessed. Results. The modified intent-to-treat population was 671 adults randomized to GEn 600 mg (n = 161), GEn 1200 mg (n = 266), or placebo (n = 244). GEn significantly improved least squares mean change in IRLS total score from baseline versus placebo for no-to-moderate (GEn 600 mg,- 12.3; 1200 mg, - 11.3; placebo, - 7.7) and severe-to-very severe (- 16.6; - 17.0; - 12.7) groups (all P < 0.01). Significantly more GEn-treated patients (both doses) were CGI-I responders (week 12) versus placebo in both sleep subgroups (all P < 0.01). GEn substantially improved mood and pain scores for both sleep subgroups versus placebo. The most frequent treatment-emergent adverse events were somnolence and dizziness. Conclusion. GEn (600 mg and 1200 mg) was effective and well tolerated in adults with moderate-to-severe primary RLS regardless of baseline sleep disturbance level.

AB - Introduction. This pooled analysis investigated the effects of gabapentin enacarbil (GEn) on clinical correlates of sleep disturbance in adults with moderate-to-severe primary restless legs syndrome (RLS) and no-to-moderate or severe-to-very severe baseline sleep disturbance. Methods. Co-primary end-points were mean change from baseline to week 12 in International Restless Legs Scale (IRLS) total score and proportion of responders ('much'/'very much' improved) on the investigator-rated Clinical Global Impression-Improvement (CGI-I) scale (week 12). Pain, mood, individual IRLS items, and safety were assessed. Results. The modified intent-to-treat population was 671 adults randomized to GEn 600 mg (n = 161), GEn 1200 mg (n = 266), or placebo (n = 244). GEn significantly improved least squares mean change in IRLS total score from baseline versus placebo for no-to-moderate (GEn 600 mg,- 12.3; 1200 mg, - 11.3; placebo, - 7.7) and severe-to-very severe (- 16.6; - 17.0; - 12.7) groups (all P < 0.01). Significantly more GEn-treated patients (both doses) were CGI-I responders (week 12) versus placebo in both sleep subgroups (all P < 0.01). GEn substantially improved mood and pain scores for both sleep subgroups versus placebo. The most frequent treatment-emergent adverse events were somnolence and dizziness. Conclusion. GEn (600 mg and 1200 mg) was effective and well tolerated in adults with moderate-to-severe primary RLS regardless of baseline sleep disturbance level.

KW - Gabapentin enacarbil

KW - Mood

KW - Pain

KW - Restless legs syndrome

UR - http://www.scopus.com/inward/record.url?scp=84930325198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930325198&partnerID=8YFLogxK

U2 - 10.3109/07853890.2015.1025825

DO - 10.3109/07853890.2015.1025825

M3 - Article

C2 - 25874578

AN - SCOPUS:84930325198

SN - 0785-3890

VL - 47

SP - 269

EP - 277

JO - Annals of Medicine

JF - Annals of Medicine

IS - 3

ER -

Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this